Fiduciary Financial Group LLC Invests $268,000 in Enovis Co. (NYSE:ENOV)

Fiduciary Financial Group LLC acquired a new stake in shares of Enovis Co. (NYSE:ENOV - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,991 shares of the company's stock, valued at approximately $268,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Confluence Investment Management LLC acquired a new position in Enovis during the 4th quarter valued at about $3,494,000. Retirement Systems of Alabama boosted its position in shares of Enovis by 10.1% during the third quarter. Retirement Systems of Alabama now owns 67,846 shares of the company's stock worth $2,921,000 after buying an additional 6,239 shares during the period. Geode Capital Management LLC boosted its position in shares of Enovis by 9.5% during the third quarter. Geode Capital Management LLC now owns 921,437 shares of the company's stock worth $39,678,000 after buying an additional 80,165 shares during the period. Barclays PLC grew its holdings in Enovis by 16.1% in the 3rd quarter. Barclays PLC now owns 368,488 shares of the company's stock worth $15,864,000 after buying an additional 51,151 shares in the last quarter. Finally, MML Investors Services LLC increased its position in Enovis by 17.2% in the 3rd quarter. MML Investors Services LLC now owns 44,179 shares of the company's stock valued at $1,902,000 after acquiring an additional 6,476 shares during the period. 98.45% of the stock is currently owned by institutional investors.

Enovis Price Performance

ENOV stock traded down $0.22 during trading hours on Thursday, hitting $45.50. 490,748 shares of the stock traded hands, compared to its average volume of 1,887,305. The stock has a 50-day simple moving average of $45.84 and a 200 day simple moving average of $44.34. The company has a market cap of $2.54 billion, a P/E ratio of -20.78 and a beta of 1.94. Enovis Co. has a one year low of $38.27 and a one year high of $65.03. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.11. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. During the same quarter last year, the firm posted $0.56 EPS. The business's revenue for the quarter was up 21.0% on a year-over-year basis. Equities analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have issued reports on ENOV shares. JMP Securities started coverage on Enovis in a research report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price target for the company. Evercore ISI reduced their price objective on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating for the company in a report on Tuesday, October 1st. Finally, Needham & Company LLC reissued a "buy" rating and set a $65.00 target price on shares of Enovis in a research note on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Enovis has an average rating of "Moderate Buy" and an average price target of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.